Jubilant Pharmova Ltd (JUBLPHARMA) — shareholding pattern, promoter holding, financials and share price
About Jubilant Pharmova Ltd (JUBLPHARMA)
Jubilant Pharmova Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as JUBLPHARMA and on the BSE under scrip code 530019. Its ISIN is INE700A01033.
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs. [1]
Jubilant Pharmova is an integrated global pharmaceutical and life‑sciences company operating radiopharmaceuticals, radiopharmacies, allergy immunotherapy, CDMO sterile injectables, CRDMO drug discovery and APIs, generics and proprietary novel oncology drugs, with six FDA‑approved manufacturing sites across North America, India and Europe and a network of radiopharmacies concentrated in the United States.
The business mix is highly dollarized and US‑centric: approximately 94% of revenues are USD denominated and ~81% of revenues derive from the USA, making Jubilant Pharmova’s commercial performance tightly linked to North American demand, reimbursement dynamics, and regulatory developments while insulating it from US tariff risk through significant Canadian origin share.
Listed peers in Pharmaceuticals: Natco Pharma Ltd, Cohance Lifesciences Ltd, Alembic Pharmaceuticals Ltd, Alivus Life Sciences Ltd, Concord Biotech Ltd, Corona Remedies Ltd.
Valuation & Returns
10 Jul 2026At ₹967.85 a share on 10 Jul 2026, Jubilant Pharmova Ltd (JUBLPHARMA) was valued at a price-to-earnings ratio of 38.78x against an industry P/E of 36.41x and a price-to-book of 2.46x on a book value of ₹392.7 per share as of Mar 2025. Solomo computes return on equity of 6.36% and return on capital employed of 9.19% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 38.78x
- Industry P/E
- 36.41x
- P/B
- 2.46x
- EPS (TTM)
- ₹24.96
- Book value / share
- ₹392.7
- ROE
- 6.36%
- ROCE
- 9.19%
- ROA
- 3.12%
- Debt / equity
- 0.44x
- Dividend yield
- 0.52%
- EBITDA margin
- 15.4%
- 52-week range
- ₹783.75 – ₹1,250
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Jubilant Pharmova Ltd (JUBLPHARMA) reported revenue of ₹8,280 crore, net profit of ₹398 crore and earnings per share of ₹25.02. That compares with revenue of ₹7,234 crore and net profit of ₹836 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹2,290 crore and net profit ₹119 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 6,130 | 6,282 | 6,703 | 7,234 | 8,280 |
| Net profit (₹ cr) | 413 | -65 | 73 | 836 | 398 |
| EPS (₹) | 25.98 | -3.83 | 4.84 | 52.69 | 25.02 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -13.64% | -24.99% | 104.07% | 7.93% |
| Profit growth | -13.79% | -43.07% | -37.46% | - |
| Stock price CAGR | 14% | 7% | 38% | -15% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 47.68% of Jubilant Pharmova Ltd (JUBLPHARMA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 15.87% and domestic institutional investors (DII) hold 12.4%. Promoters have pledged 6.6% of their holding. Market capitalisation was ₹15,416 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: REKHA JHUNJHUNWALA 3.28%, BANDHAN SMALL CAP FUND 3.21%, REKHA JHUNJHUNWALA 3.15%, GOVERNMENT PENSION FUND GLOBAL 3.1%, EAST BRIDGE CAPITAL MASTER FUND I LTD 2.53%, KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK MULTICAP FUND 2.41%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 47.68% | 6.6% | 15.87% | 12.4% | 51.77% |
| Mar 2026 | 47.68% | 5.4% | 15.9% | 11.62% | 51.76% |
| Dec 2025 | 47.68% | 5.4% | 15.96% | 11.22% | 51.75% |
| Sep 2025 | 47.68% | 5.4% | 16.57% | 10.52% | 51.69% |
| Jun 2025 | 47.68% | - | 17.4% | 9.53% | 51.77% |
| Mar 2025 | 50.68% | - | 17.22% | 7.05% | 48.77% |
| Dec 2024 | 50.68% | - | 16.96% | 6.98% | 48.77% |
| Sep 2024 | 50.68% | - | 17.94% | 5.66% | 48.77% |